CMRX Earnings Prediction
The chart below shows how CMRX performed 10 days before and after its earnings report, based on data from the past quarters. Typically, CMRX sees a +17.85% change in stock price 10 days leading up to the earnings, and a +3.05% change 10 days following the report. On the earnings day itself, the stock moves by -8.48%. This data can give you a slight idea of what to expect for the next quarter's release.
CMRX Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
26.00K
136.36%
-79.84%
Gross Margin
--
--
--
Operating Margin
-95357.69%
-60.70%
438.77%
Net Margin
-87996.15%
-59.64%
448.78%
EPS
-0.26
-3.70%
13.04%
No Data Available
CMRX Earnings Analysis
Chimerix, Inc. Corporation (CMRX.O) Earnings Conference Call
Positive
Net Loss Improvement: In the third quarter of 2024, the company reported a net loss of $22.9 million, an improvement compared to a net loss of $24 million in the third quarter of 2023.
R&D Expense Increase: Research and development expenses increased to $19.6 million for the third quarter of 2024 compared to $17.4 million for the same period of 2023, driven primarily by increased spending in the ACT ION study.
Administrative Expense Reduction: General and administrative expenses decreased to $5.2 million for the third quarter of 2024 compared to $9.3 million for the same period in 2023, reflecting a reduction in one-time non-cash expenses related to historical grants.
Strong Cash Position: The company ended the third quarter with just over $152 million in cash and cash equivalents, providing a solid financial foundation for future operations.
Cash Management Commitment: The company is committed to sensible cash management, with a cash runway extending into the fourth quarter of 2026.
Negative
Net Loss Comparison: For the third quarter of 2024, we reported a net loss of $22.9 million compared to a net loss of $24 million in the third quarter of 2023.
R&D Expense Increase: Research and development expenses increased to $19.6 million for the third quarter of 2024 compared to $17.4 million for the same period of 2023.
Increased Spending Impact: This was primarily driven by increased spending in the ACT ION study.
Administrative Expense Reduction: General and administrative expenses decreased to $5.2 million for the third quarter of 2024 compared to $9.3 million for the same period in 2023.
Cash and Cash Equivalents: We ended the third quarter with just over $152 million in cash and cash equivalents.
CMRX FAQs
How does CMRX typically perform around its earnings report dates?
Is Chimerix, Inc. (CMRX) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
CMRX Earning Call Sentiment
Chimerix, Inc. (CMRX) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
CMRX.O
70.56%Positive
The earnings call reveals mixed signals. Financial performance shows slight improvements with reduced net loss and decreased G&A expenses, but increased R&D expenses and ongoing net loss pose financial risks. The cash runway until 2026 is positive, but regulatory and operational risks remain. The Q&A highlights management's preparation for NDA submissions and commercialization efforts, but analysts' sentiment is cautious due to unclear responses on certain risks. Overall, the sentiment is neutral as positive and negative factors balance each other out.
